Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.
Reads0
Chats0
TLDR
In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor.Abstract:
Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.read more
Citations
More filters
Journal ArticleDOI
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.
Umberto Malapelle,Sara Pilotto,Francesco Passiglia,Francesco Pepe,Pasquale Pisapia,Luisella Righi,Angela Listì,Paolo Bironzo,Lorenzo Belluomini,Fabrizio Tabbò,Maria Lucia Reale,Gianluca Russo,Caterina De Luca,Silvia Novello,Giancarlo Troncone +14 more
TL;DR: A review of different detection platforms and therapeutic options currently available for the clinical management of advanced EGFR-positive NSCLC, summarizing scientific evidence and describing molecular testing as well as treatment practice in the real-word scenario is provided in this article.
Journal ArticleDOI
Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
Florian Janke,Farastuk Bozorgmehr,Sabine Wrenger,Steffen Dietz,Claus P. Heussel,G. Heussel,Carlos Francisco Silva,Stephan Rheinheimer,Manuel Feisst,Mike Thomas,Heiko Golpon,Andreas Günther,Holger Sültmann,Thomas Muley,Sabina Janciauskiene,Michael Meister,Marc A. Schneider +16 more
TL;DR: It is demonstrated that an early measurement of biomarkers immediately after therapy start can assess tumor response to treatment and might support an adaptation of treatment to improve patients’ outcome.
Journal ArticleDOI
Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer
Etienne Gouton,N. Malissen,Nicolas André,Arnaud Jeanson,Annick Pelletier,Albane Testot-Ferry,Caroline Gaudy-Marqueste,Laetitia Dahan,Emeline Tabouret,Thomas Chevalier,Laurent Greillier,Pascale Tomasini +11 more
TL;DR: Routine cfDNA molecular profiling is feasible and can lead to the access of targeted therapies, however, no notable benefit in patient’s outcomes was shown in this unselected pan-cancer study.
Journal ArticleDOI
Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs
Roberta Belli,Elisabetta Ferraro,Alessio Molfino,Raffaella Carletti,Federica Tambaro,Paola Costelli,Maurizio Muscaritoli +6 more
TL;DR: The current knowledge on circulating muscular miRNAs involved in muscle atrophy is summarized, since they might represent easily accessible and promising biomarkers of cachexia and might allow an early diagnosis of this syndrome.
Journal ArticleDOI
High-Sensitive Detection of Small-Cell Lung Cancer Cells Based on Terminal Deoxynucleotidyl Transferase-Mediated Extension Polymerization Aptamer Probe.
TL;DR: In this article, a terminal deoxynucleotidyl transferase (TdT)-mediated extension polymerization aptamer probe (denoted as TEPAP) was designed for the detection of small-cell lung cancer (SCLC).
References
More filters
Journal ArticleDOI
The functions of animal microRNAs
TL;DR: Evidence is mounting that animal miRNAs are more numerous, and their regulatory impact more pervasive, than was previously suspected.
Journal ArticleDOI
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
TL;DR: It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer.
Journal ArticleDOI
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
Xi Chen,Yi Ba,Lijia Ma,Lijia Ma,Xing Cai,Yuan Yin,Kehui Wang,Jigang Guo,Yujing Zhang,Jiangning Chen,Xing Guo,Qibin Li,Qibin Li,Xiaoying Li,Wenjing Wang,Yan Zhang,Jin Wang,Xueyuan Jiang,Yang Xiang,Chen Xu,Pingping Zheng,Juanbin Zhang,Ruiqiang Li,Hongjie Zhang,Xiaobin Shang,Ting Gong,Guang Ning,Jun Wang,Jun Wang,Ke Zen,Junfeng Zhang,Chen-Yu Zhang +31 more
TL;DR: It is demonstrated that miRNAs are present in the serum and plasma of humans and other animals such as mice, rats, bovine fetuses, calves, and horses, and can serve as potential biomarkers for the detection of various cancers and other diseases.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma
Jason D. Arroyo,John R. Chevillet,Evan M. Kroh,Ingrid K. Ruf,Colin C. Pritchard,Donald F. Gibson,Patrick S. Mitchell,Christopher F. Bennett,Era L. Pogosova-Agadjanyan,Derek L. Stirewalt,Jonathan F. Tait,Muneesh Tewari +11 more
TL;DR: Identification of extracellular Ago2–miRNA complexes in plasma raises the possibility that cells release a functional miRNA-induced silencing complex into the circulation, and reveals two populations of circulating miRNAs and suggest that circulating Ago2 complexes are a mechanism responsible for the stability of plasma mi RNAs.
Related Papers (5)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo,Philip C. Mack,Giorgio V. Scagliotti,Paul Baas,Fabrice Barlesi,Trever G. Bivona,Roy S. Herbst,Tony Mok,Nir Peled,Robert Pirker,Luis E. Raez,Martin Reck,Jonathan W. Riess,Lecia V. Sequist,Frances A. Shepherd,Lynette M. Sholl,Daniel Shao-Weng Tan,Heather A. Wakelee,Ignacio I. Wistuba,Murry W. Wynes,David P. Carbone,Fred R. Hirsch,David R. Gandara +22 more